Cholera Vaccines Market Size, Share & Trends Report

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

  • Published Date: Aug, 2018
  • Base Year for Estimate: 2017
  • Report ID: GVR-1-68038-069-9
  • Format: Electronic (PDF)
  • Historical Data: 2013 - 2016
  • Number of Pages: 87

Industry Insights

The global cholera vaccines market size was estimated at USD 63.1 million in 2017 and will exhibit a CAGR of 8.2% during the forecast period. High disease incidence rate and increasing need for its prevention are some of the key factors expected to boost the market.

Europe cholera vaccines market

The WHO Global Task Force on Cholera Control (GTFCC) aims to reduce the incidence of deaths resulting from the disease by 90.0% with the help of a strategy titled “Ending Cholera: A Global Roadmap to 2030”. With the help of GTFCC, oral cholera vaccines (OCV) are made available all over the world to ensure immunization, especially in cholera-prone areas of Africa and Asia. The Multi-Sectoral Cholera Prevention and Control Plan (MCPCP) for 2011 to 2016 was implemented in Kenya in partnership with UNICEF to prevent the disease. Moreover, in December 2012, the United Nations announced an initiative in Haiti and the Dominican Republic to eliminate the disease.

The worldwide coverage of immunization is steadily rising. A survey conducted by WHO in 2014 estimated that about 3,175, 206 doses of Dukoral and Shanchol were deployed in vaccination campaigns around the world between 1997 and 2014. In affected areas, larger number of doses were utilized; vaccines are still, however, underused considering the fact that 1.4 billion people are at risk. According to WHO, the global supply of OCV was pegged at an estimated 6 million in 2016, thanks to the addition of a prequalified vaccine producer.

According to an article published by WHO in 2017, each year 1.3 to 4.0 million cases of cholera are reported and 21,000 to 143,000 deaths occur globally. In 2015, 172,454 cases were reported and 1304 deaths occurred due to cholera across 42 countries. Lack of clean water and proper sanitation increases the risk of people developing the disease. Almost 2.4 billion people lack adequate facilities of sanitation and 1.8 billion people in the world drink water contaminated with feces, which carries cholera bacterium. Thus, increasing risk factors are sure to support the demand for vaccination against the disease, aiding market growth.

Product Insights

Based on product, the cholera vaccines market is categorized into Dukoral, Shanchol, and Vaxchora. The Dukoral vaccine dominated the overall market in terms of revenue in 2017 owing to the established stockpile of this OCV by WHO. It is the only vaccine that provides protection against diarrhea caused by heat-labile-toxin-producing E. coli.

The Vaxchora vaccine is expected to witness fastest growth over the forecast period due its advantages such as single dose immunization and reduced adverse effects. In June 2016, FDA approved a single-dose live attenuated OCV, Vaxchora, indicated for use in adults between the age of 18 and 64. According to Center for Infectious Disease Research and Policy, in the immunogenicity trials of Vaxchora carried out in Australia and U.S., 90% of adults vaccinated developed antibodies, which provide immunity against the disease.

Regional Insights

Europe and Asia Pacific spearheaded the market by contributing to over 55.0% of the overall revenue in 2017. Asia Pacific dominated the global market in 2017, followed by Europe. Key factors contributing toward the APAC’s dominance are increasing incidence of cholera and growing importance of immunization. The launch of Shanchol, an OCV, in 2009 resulted in an increase in demand for immunization in the region.

Global cholera vaccines market

North America is expected to grow at a lucrative rate over the forecast period due to the introduction of the first and only OCV, Vaxchora, in U.S. Furthermore, the number of people traveling to countries with sudden outbreaks of cholera is increasing and demand for immunization is growing. North America is projected to record a significant CAGR of over 13.0% over the forecast period.

Cholera Vaccines Market Share Insights

Some of the key players dominating the market are Shantha Biotechnics Private Limited; PaxVax, Inc.; and Valneva SE. Key players focus on development of their product portfolio and mergers and acquisitions to gain a strong foothold in the market. For instance, Valneva SE acquired Crucell Sweden AB and all privileges, assets, and licenses associated with Dukoral, a vaccine that prevents cholera, to strengthen its product portfolio.

Report Scope

Attribute

Details

Base year for estimation

2017

Actual estimates/Historical data

2013 - 2016

Forecast period

2017 - 2025

Market representation                                 

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, India, Brazil, South Africa

Report coverage      

Revenue forecast, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analysts working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2017 to 2025. For the purpose of this study, Grand View Research has segmented the global cholera vaccines market report on the basis of product and region:

  • Product Outlook (Revenue, USD Million, 2013 - 2025)

    • Dukoral

    • Shanchol

    • Vaxchora

    • Others

  • Regional Outlook (Revenue, USD Million, 2013 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • India

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa 

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
Compass Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified